| Anhui Zhifei Longcom COVID-19 vaccine |
Not yet available |
Not yet available |
Not yet available |
Not yet available |
Not yet available |
| Bharat Biotech COVID-19 vaccine |
Additional doses of a vaccine may be needed as part of an extended primary series for target populations where the immune response following the standard primary series is deemed likely to be insufficient.
The objective of including an additional dose in the primary series is to increase the proportion of individuals who are protected against disease Emerging evidence suggests that older persons and immunocompromised individuals mount a lower immune response after a standard primary series compared to younger individuals and those without immunocompromising conditions. Therefore, for older adults and immunocompromised persons who have received a standard 2-dose primary series of BBV152 COVID-19 vaccine, WHO recommends an additional dose.
In situations of interrupted supply of the vaccine used for the primary series, or for countries with access to COVID-19 vaccines from another vaccine platform that has received WHO emergency use listing, a heterologous third dose can be considered. |
Emerging evidence suggests that older persons and immunocompromised individuals mount a lower immune response after a standard primary series compared to younger individuals and those without immunocompromising conditions. Therefore, for older adults and immunocompromised persons who have received a standard 2-dose primary series of BBV152 COVID-19 vaccine, WHO recommends an additional dose |
It is currently recommended that the same product be used for both doses. Recommendations may be updated as further information becomes available. If different COVID-19 vaccines are inadvertently administered in the two doses, no additional doses of either vaccine are recommended at this time. |
WHO recommends the use of the Bharat Biotech COVID-19 vaccine in pregnant women when the benefits of vaccination outweigh the potential risks.
WHO does not recommend pregnancy testing prior to vaccination.
WHO does not recommend delaying pregnancy or terminating pregnancy because of vaccination. |
Not yet available |
| CanSino COVID-19 vaccine |
Not yet available |
Not yet available |
Not yet available |
|
Not yet available |
| EU Nodes-AstraZeneca/ Oxford; AstraZeneca/SK BIO; Serum Institute of India COVID-19 vaccine |
Additional doses of a vaccine may be needed as part of an extended primary series for target populations where the immune response rate following the standard primary series is deemed insufficient. In particular, immunocompromised individuals often fail to mount a protective immune response after a standard primary series, but also older adults may respond poorly to a standard primary series. |
Additional doses of a vaccine may be needed as part of an extended primary series for target populations where the immune response rate following the standard primary series is deemed insufficient. In particular, immunocompromised individuals often fail to mount a protective immune response after a standard primary series, but also older adults may respond poorly to a standard primary series. |
All ChAdOx1-S [recombinant] products covered by this recommendation (AstraZeneca COVID-19 AZD1222 - Vaxzevria, SII COVISHIELD™) are considered equivalent and interchangeable for both ChAdOx1-S [recombinant] doses.
With regards to using ChAdOx1-S [recombinant] products with other COVID-19 vaccines, WHO recommends that the same COVID-19 vaccine should be used for both doses. If different COVID-19 vaccines are inadvertently administered in the two doses, no additional doses of either vaccine are recommended at this time. |
WHO recommends the use of the AstraZeneca COVID-19 vaccine in pregnant women when the benefits of vaccination to the pregnant woman outweigh the potential risks.
WHO does not recommend pregnancy testing prior to vaccination.
WHO does not recommend delaying pregnancy or terminating pregnancy because of vaccination. |
Individuals younger than 18 years of age should not be routinely vaccinated with the AstraZeneca COVID-19 vaccine. |
| Gamaleya Sputnik V; Sputnik Light COVID-19 vaccine |
Not yet available |
Not yet available |
Not yet available |
|
Not yet available |
| Instituto Finlay COVID-19 vaccine |
Not yet available |
Not yet available |
Not yet available |
Not yet available |
Not yet available |
| Janssen COVID-19 vaccine |
Not yet available |
The administration of the second dose will result in increased individual-level protection against symptomatic infection, and against severe disease. WHO recommends an interdose interval of 2 to 6 months. The choice for the inter-dose interval depends on the epidemiological situation, and needs for certain subpopulations. |
Evidence suggests that heterologous COVID-19 vaccine schedules (using WHO EUL vaccine products from different platforms) may be more immunogenic and effective than homologous schedules, depending on the specific platforms and order of the products used. |
WHO recommends the use of the AstraZeneca COVID-19 vaccine in pregnant women when the benefits of vaccination to the pregnant woman outweigh the potential risks.
WHO does not recommend pregnancy testing prior to vaccination.
WHO does not recommend delaying pregnancy or terminating pregnancy because of vaccination. |
Vaccination of individuals below 18 years of age is not routinely recommended. Until such data are available, vaccination of individuals below 18 years of age is not routinely recommended. |
| Moderna COVID-19 vaccine |
The additional primary dose is indicated in:
- Moderately or severely immunocompromised persons who received an initial mRNA COVID-19 vaccine primary series should receive an additional primary dose of the same mRNA COVID-19 vaccine administered for the primary series, as follow:
Moderna: 100 µg in a volume of 0.5 mL for persons aged 18 years and older.
- The additional primary dose (i.e., third dose) of an mRNA COVID-19 vaccine should be administered at least 28 days after completion of the initial 2-dose mRNA COVID-19 primary series.
- If the additional primary dose of an mRNA COVID-19 vaccine is given fewer than 24 days after the second dose (i.e., administered earlier than the 4-day grace period), the additional primary dose should be repeated. The repeat dose should be spaced from the date of the dose given in error by the recommended minimum interval.
- These additional primary dose recommendations also apply to people who received two doses of different mRNA COVID-19 vaccine products for their primary series.
In situations of interrupted supply of the vaccine used for the primary series, or for countries with access to COVID-19 vaccines from another vaccine platform that has received WHO emergency use listing, a heterologous third dose can be considered for those requiring an additional dose in the primary vaccination series. |
In particular, immunocompromised individuals often fail to mount a protective immune response after a standard primary series, but also older adults may respond poorly to a standard primary series |
To date recommended that the same product should be used for both doses. If different COVID-19 vaccine products are administered in the two-dose primary vaccination series, no additional doses of either homologous or heterologous vaccine are recommended at this time.
In situations of interrupted supply of vaccine used for the first dose, a heterologous second dose can be considered.
Recommendations will be updated as further information becomes available on interchangeability. |
WHO recommends the use of the Moderna COVID-19 vaccine in pregnant women. |
A Phase 3 trial in children aged 12-17 years indicated likely high efficacy and good safety in this age group.
Countries should consider using the Moderna COVID-19 vaccine in children aged 12 to 17 only when high vaccine coverage with 2 doses has been achieved in higher priority groups. Children 12-17 years of age with comorbidities that put them at significantly higher risk of serious COVID-19 disease, alongside other high-risk groups, maybe offered vaccination.
There are currently no efficacy or safety data for children below the age of 12 years. Until such data are available, individuals below 12 years of age should not be routinely vaccinated. |
| Novavax COVID-19 vaccine |
Not yet available |
Emerging evidence suggests that older persons and immunocompromised individuals mount a lower immune response after a standard primary series compared to younger individuals and those without immunocompromising conditions. Therefore, for older adults and immunocompromised persons who have received a standard 2-dose primary series of Novavax COVID-19 vaccine, WHO recommends an additional (third) dose. |
Homologous schedules are considered standard practice because of the substantial safety, immunogenicity, and efficacy data available for each WHO EUL COVID-19 vaccine.
WHO supports a flexible approach to homologous versus heterologous vaccination schedules, and considers two heterologous doses of any EUL COVID-19 vaccine to be a complete primary series.
Heterologous vaccination should be implemented with careful consideration of current vaccine supply, vaccine supply projections, and other access considerations, alongside the potential benefits and risks of the specific products being used. |
WHO recommends the use of NVX-CoV2373 vaccine in pregnant women if the benefits of vaccination to the pregnant woman outweigh the potential risks.
WHO does not recommend pregnancy testing prior to vaccination.
WHO does not recommend delaying pregnancy or terminating pregnancy because of vaccination. |
Not yet available |
| Pfizer-BioNTech COVID-19 vaccine |
The additional primary dose is indicated in:
- Moderately or severely immunocompromised persons who received an initial mRNA COVID-19 vaccine primary series should receive an additional primary dose of the same mRNA COVID-19 vaccine administered for the primary series, as follow: Pfizer-BioNTech: 30 µg in a volume of 0.3 mL for persons aged 12 years and older.
- The additional primary dose (i.e., third dose) of an mRNA COVID-19 vaccine should be administered at least 28 days after completion of the initial 2-dose mRNA COVID-19 primary series.
- If the additional primary dose of an mRNA COVID-19 vaccine is given fewer than 24 days after the second dose (i.e., administered earlier than the 4-day grace period), the additional primary dose should be repeated. The repeat dose should be spaced from the date of the dose given in error by the recommended minimum interval.
- These additional primary dose recommendations also apply to people who received two doses of different mRNA COVID-19 vaccine products for their primary series.
In situations of interrupted supply of the vaccine used for the primary series, or for countries with access to COVID-19 vaccines from another vaccine platform that has received WHO emergency use listing, a heterologous third dose can be considered for those requiring an additional dose in the primary vaccination series. |
|
To date recommended that the same product should be used for both doses. If different COVID-19 vaccine products are inadvertently administered in the two doses, no additional doses of either homologous or heterologous vaccine are recommended at this time.
In situations of interrupted supply of vaccine used for the first dose, a heterologous second dose can be considered.
Recommendations will be updated as further information becomes available on interchangeability. |
WHO recommends the use of the Pfizer-BioNTech COVID-19 vaccine in pregnant women.
WHO does not recommend pregnancy testing prior to vaccination.
WHO does not recommend delaying pregnancy or terminating a pregnancy because of vaccination. |
A Phase 3 trial in children 12-15 years of age showed high efficacy and good safety in this group, leading to an extension of the previous age indication from 16 years onwards down to age 12 onwards.
To date, no efficacy or safety data for children younger than 12 years. Until such data are available, individuals below 12 years of age should not be routinely vaccinated.
WHO recommends that countries should consider using the Pfizer-BioNTech COVID-19 vaccine in children 12-15 years of age only when high vaccine coverage with 2 doses has been achieved in the high priority groups.
Children 12-15 years of age with comorbidities that put them at significantly higher risk of serious COVID-19 disease, alongside other high-risk groups, maybe offered vaccination. |
| Sinopharm/BIBP COVID-19 vaccine |
Additional doses of a vaccine may be needed as part of an extended primary series for target populations where the immune response following the standard primary series is deemed likely to be insufficient.
The objective of including an additional dose in the primary series is to increase the proportion of individuals who are protected against disease Emerging evidence suggests that older persons and immunocompromised individuals mount a lower immune response after a standard primary series compared to younger individuals and those without immunocompromising conditions. Therefore, for older adults and immunocompromised persons who have received a standard 2-dose primary series of Sinopharm/BIBP COVID-19 vaccine, WHO recommends an additional dose.
In situations of interrupted supply of the vaccine used for the primary series, or for countries with access to COVID-19 vaccines from another vaccine platform that has received WHO emergency use listing, a heterologous third dose can be considered. |
WHO recommends an additional dose for older adults and immunocompromised persons who have received a standard 2-dose primary series of the Sinopharm/BIBP COVID-19 vaccine. Advice as to whether the additional dose should be a homologous or heterologous vaccine (COVID-19 vaccines from another vaccine platform such as mRNA or viral-vectored vaccines) will be updated once more data are available. |
WHO recommends that the same COVID-19 vaccine should be used for both doses. |
WHO recommends the use of the Sinopharm/BIBP COVID-19 vaccine in pregnant women when the benefits of vaccination to the pregnant woman outweigh the potential risks.
WHO does not recommend pregnancy testing prior to vaccination.
WHO does not recommend delaying pregnancy or terminating pregnancy because of vaccination. |
Not yet available |
| Sinopharm/WIBP COVID-19 vaccine |
Not yet available |
Not yet available |
Not yet available |
Not yet available |
Not yet available |
| Sinovac COVID-19 vaccine |
Additional doses of a vaccine may be needed as part of an extended primary series for target populations where the immune response following the standard primary series is deemed likely to be insufficient.
The objective of including an additional dose in the primary series is to increase the proportion of individuals who are protected against disease Emerging evidence suggests that older persons and immunocompromised individuals mount a lower immune response after a standard primary series compared to younger individuals and those without immunocompromising conditions. Therefore, for older adults and immunocompromised persons who have received a standard 2-dose primary series of Sinovac COVID-19 vaccine, WHO recommends an additional dose.
In situations of interrupted supply of the vaccine used for the primary series, or for countries with access to COVID-19 vaccines from another vaccine platform that has received WHO emergency use listing, a heterologous third dose can be considered. |
Emerging evidence suggests that older persons and immunocompromised individuals mount a lower immune response after a standard primary series compared to younger individuals and those without immunocompromising conditions. Therefore, for older adults and immunocompromised persons who have received a standard 2-dose primary series of Sinovac-CoronaVac, WHO recommends an additional dose |
It is currently recommended that the same product should be used for both doses. |
WHO recommends the use of the Sinovac-CoronaVac vaccine in pregnant women when the benefits of vaccination outweigh the potential risks.
WHO does not recommend pregnancy testing prior to vaccination.
WHO does not recommend delaying pregnancy or terminating pregnancy because of vaccination. |
Not yet available |
| Vector Institute COVID-19 vaccine |
Not yet available |
Not yet available |
Not yet available |
Not yet available |
Not yet available |
| CIGB (Abdala) COVID-19 vaccine |
Not yet available |
Not yet available |
Not yet available |
Not yet available |
Not yet available |